2-氯-5,6-二氟苯并噻唑 | 960535-39-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 2-氯-5,6-二氟苯并噻唑
• 中文别名: 2-氯-5,6-二氟苯并[d]噻唑
• 英文名称: 2-Chloro-5,6-difluorobenzo[d]thiazole
• 英文别名: 2-chloro-5,6-difluoro-1,3-benzothiazole
• CAS: 960535-39-1
• 化学式: C₇H₂ClF₂NS
• 分子量: 205.615
• InChiKey: YMEIUMKOBQLKJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-氯-5,6-二氟苯并噻唑 在 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N1-(5,6-difluorobenzo[d]thiazol-2-yl)propane-1,3-diamine
  参考文献：
  名称：

  Preparation, antibacterial evaluation and preliminary structure–activity relationship (SAR) study of benzothiazol- and benzoxazol-2-amine derivatives

  摘要：

  In this study, a novel benzothiazol- and benzooxazol-2-amine scaffold with antibacterial activity was designed and synthesized. Preliminary structure-activity relationship analysis displayed that compound 8t with a 5,6-difluorosubstituted benzothiazole was found to be a potent inhibitor of Gram-positive pathogens, and exhibited some potential against drug-resistant bacteria and without cytotoxicity in therapeutic concentrations. In addition, molecular docking studies indicated that Staphylococcus aureus methionyl-tRNA synthetase might be the possible target of these compounds. Taken together, the present study provides an effective entry to the synthesis of a good lead for subsequent optimization and a new small molecule candidate drug for antibacterial therapeutics. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.079
• 作为产物：
  描述：

  3,4-二氟苯胺 在 氯化亚砜 、 盐酸肼 、 溴 、 一水合肼 、 溶剂黄146 作用下， 以 乙二醇 为溶剂， 反应 4.5h， 生成 2-氯-5,6-二氟苯并噻唑
  参考文献：
  名称：

  Preparation, antibacterial evaluation and preliminary structure–activity relationship (SAR) study of benzothiazol- and benzoxazol-2-amine derivatives

  摘要：

  In this study, a novel benzothiazol- and benzooxazol-2-amine scaffold with antibacterial activity was designed and synthesized. Preliminary structure-activity relationship analysis displayed that compound 8t with a 5,6-difluorosubstituted benzothiazole was found to be a potent inhibitor of Gram-positive pathogens, and exhibited some potential against drug-resistant bacteria and without cytotoxicity in therapeutic concentrations. In addition, molecular docking studies indicated that Staphylococcus aureus methionyl-tRNA synthetase might be the possible target of these compounds. Taken together, the present study provides an effective entry to the synthesis of a good lead for subsequent optimization and a new small molecule candidate drug for antibacterial therapeutics. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.079

文献信息

• Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same
  申请人：Yuhan Corporation

  公开号：US10383859B2

  公开（公告）日：2019-08-20

  The present invention provides a benzo[d]thiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzo[d]thiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the benzo[d]thiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.

  本发明提供了一种苯并[d]噻唑衍生物或其药学上可接受的盐、其制备工艺以及包含其的药物组合物。苯并[d]噻唑衍生物或其药学上可接受的盐可以选择性地抑制 KRS 与层粘连蛋白受体（LR）之间的蛋白-蛋白相互作用，从而抑制癌细胞的迁移。因此，苯并[d]噻唑衍生物或其药学上可接受的盐可用于预防或治疗与癌细胞转移相关的疾病。
• BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME
  申请人：Yuhan Corporation

  公开号：EP3483149B1

  公开（公告）日：2021-01-13
• Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same
  申请人：Yuhan Corporation

  公开号：US20190142809A1

  公开（公告）日：2019-05-16

  The present invention provides a benzo[d]thiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzo[d]thiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the benzo[d]thiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.
• Preparation, antibacterial evaluation and preliminary structure–activity relationship (SAR) study of benzothiazol- and benzoxazol-2-amine derivatives
  作者：Liang Ouyang、Yuhui Huang、Yuwei Zhao、Gu He、Yongmei Xie、Jie Liu、Jun He、Bo Liu、Yuquan Wei

  DOI：10.1016/j.bmcl.2012.03.079

  日期：2012.5

  In this study, a novel benzothiazol- and benzooxazol-2-amine scaffold with antibacterial activity was designed and synthesized. Preliminary structure-activity relationship analysis displayed that compound 8t with a 5,6-difluorosubstituted benzothiazole was found to be a potent inhibitor of Gram-positive pathogens, and exhibited some potential against drug-resistant bacteria and without cytotoxicity in therapeutic concentrations. In addition, molecular docking studies indicated that Staphylococcus aureus methionyl-tRNA synthetase might be the possible target of these compounds. Taken together, the present study provides an effective entry to the synthesis of a good lead for subsequent optimization and a new small molecule candidate drug for antibacterial therapeutics. (C) 2012 Elsevier Ltd. All rights reserved.